Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
Information source: John H. Stroger Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Mellitus Type 2; Severe Hyperglycemia - Blood Glucose Level >300mg/dl.
Intervention: Glipizide XL (Drug); Saxagliptin + Metformin XR (Drug); Metformin XR (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: John H. Stroger Hospital Official(s) and/or principal investigator(s): Ambika Babu, MD,MS, Principal Investigator, Affiliation: John H Stroger Hospital of Cook County
Summary
Saxagliptin + Metformin XR (S+M) will be effective in stabilizing blood glucose (BG) levels
in patients with newly diagnosed type 2 diabetes (T2DM) with severe hyperglycemia (BG levels
300 to 450 mg/dl) and glucose toxicity and with no criteria for inpatient admission or
occurrence of severe hypoglycemia compared to glipizide XL.
The study may provide preliminary evidence to support the role of S+M as a bridging,
stabilizing and safe therapy in patients with severe hyperglycemia
Clinical Details
Official title: A Pilot Study of Outpatient Discharge Therapy With Saxagliptin + Metformin XR or Sulphonylurea for Recently Diagnosed Type 2 Diabetes Presenting With Severe Hyperglycemia
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The proportion of responders in each arm. Responder: FBG 70-300 and/or PPBG <400 mg/dl (week1-6), FBG 70-250 and/or PPBG <300 mg/dl (week 7-12) and without metabolic exclusion criteria, repeat ED visits, hospitalization or significant hypoglycemia.
Secondary outcome: Proportion of patients achieving FBG goal of 70-130 mg/dl at 12 weeks in the 2 treatment armsPercentage of patients with symptomatic hypoglycemia To measure percentage compliance with medication in the two treatment arms. The number of fold increase in beta cell function in the 2 arms.
Detailed description:
There is very little information regarding diabetes discharge regimens for patients with
recently diagnosed diabetes (<1 year duration) who present with severe hyperglycemia (blood
glucose 300-450 mg/dl) to the ED or other clinical settings and who do not need to be
admitted.
A combination of Saxagliptin+Metformin XR, could be a potential drug combination to be
tested as an initial treatment in these circumstances compared to Glipizide XL which was
shown to be effective in our previous study. We expect Saxagliptin to improve beta cell
function and decrease glucagon levels as was shown for the DPP-IV class medications and in
turn improve blood glucose levels, while Metformin XR may reduce insulin resistance and
hepatic glucose output. Such discharge therapy may help to prevent deterioration into acute
metabolic complications (DKA or hyperosmolar states) and avoid hospitalization. A high
proportion of patients may achieve glycemic targets without significant hypoglycemia as
measured by self glucose monitoring and objectively by continuous glucose monitoring system
(CGMS). Such an easy regimen may safely bridge the time gap until patients will be seen by
their providers.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Target Population
1. Subjects recently diagnosed with T2DM (less than 1 year duration) who are either
drug naïve or who had not taken oral anti-diabetic agents or insulin for more
than 2 weeks.
2. FBG and or RBG > 300mg/dl and < 450mg/dl
2. Age and Sex
1. Men and women aged 18 to 75 years of age.
2. Women of childbearing potential (WOCBP) must be using an adequate method of
contraception to avoid pregnancy throughout the study and for up to 4 weeks
after the last dose of study drug to minimize the risk of pregnancy.
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or
equivalent units of HCG) within 72 hours before the start of the investigational product.
Exclusion Criteria:
1. Sex and Reproductive Status
1. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy
for the entire study period and for up to 4 weeks after the last dose of study
drug.
2. Women who are pregnant or breastfeeding.
3. Women with a positive pregnancy test.
4. Sexually active fertile men not using effective birth control if their partners
are WOCBP.
2. Target Disease Exceptions
1. Type 2 diabetes with weight less than 120 pounds
2. Type 1 diabetes
3. History of diabetic ketoacidosis or hyperosmolar nonketotic coma
3. Medical History and Concurrent Diseases
1. Age >75 years
2. History of congestive heart failure
3. Evidence of an impaired sensorium and/or dementia
4. Current history of alcohol or substance abuse
5. Patients with any acute or active chronic medical illness
4. Physical and Laboratory Test Findings
1. FBG and /or RGB < 300 mg/dl or >450 mg/dl
2. Unstable vitals signs (temperature >101 degrees Fahrenheit, systolic blood
pressure <90 or >180 mmhg, diastolic blood pressure <60 or >110 mmhg, heart rate
<60 or >120 beats/minute)
3. Electrolyte imbalances (serum bicarbonate level <20 mEq/L, serum sodium <125 or
>150 mEq/L, serum potassium <3. 5 or >5. 5 mEq/L), serum creatinine more than 1. 5
in males and 1. 4 in females, creatinine clearance less than 60ml/min, liver
enzymes 3 times above upper limit of normal range.
4. HbA1c > 12% (based on our previous study (4) patients with HbA1c of >12 had a
high rate of non-responders)
5. Liver enzymes 3 times above upper limit of normal range.
6. Allergies and Adverse Drug Reactions - Subjects with a history of any serious
hypersensitivity reaction to saxagliptin, glipizide or metformin XR.
5. Prohibited Treatments and/or Therapies
a)Treatment with systemic cytochrome P450 3A4 (CYP 3A4) inhibitors.
6. Other Exclusion Criteria
1. Prisoners or subjects who are involuntarily incarcerated.
2. Subjects who are compulsorily detained for treatment of either a psychiatric or
physical (eg, infectious disease) illness.
Locations and Contacts
John Stroger Hospital of Cook County, Chicago, Illinois 60612, United States; Not yet recruiting Ambika Babu, M.D., Phone: 312-864-0543, Email: Ambika_Babu@rush.edu Leon Fogelfeld, M.D., Phone: 312-864-0539, Email: lfogelfe@cchil.org Ambika Babu, M.D., Principal Investigator
John Stroger Hospital of Cook County, Chicago, Illinois 60612, United States; Recruiting Ambika Babu, M.D., Phone: 312-864-0543, Email: aamblee@hotmail.com Leon Fogelfeld, M.D., Phone: 312-864-0539, Email: lfogelfe@cchil.org Ambika Babu, M.D., Principal Investigator
Additional Information
Starting date: December 2010
Last updated: April 15, 2011
|